CR20190113A - Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma - Google Patents

Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma

Info

Publication number
CR20190113A
CR20190113A CR20190113A CR20190113A CR20190113A CR 20190113 A CR20190113 A CR 20190113A CR 20190113 A CR20190113 A CR 20190113A CR 20190113 A CR20190113 A CR 20190113A CR 20190113 A CR20190113 A CR 20190113A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutically acceptable
synthesis
acceptable salts
invención
compuesto
Prior art date
Application number
CR20190113A
Other languages
English (en)
Inventor
Matt Beaver
Sheng Cui
Xianqing Shi
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20190113A publication Critical patent/CR20190113A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/36Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/1616Coordination complexes, e.g. organometallic complexes, immobilised on an inorganic support, e.g. ship-in-a-bottle type catalysts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D301/00Preparation of oxiranes
    • C07D301/02Synthesis of the oxirane ring
    • C07D301/03Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds
    • C07D301/12Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with hydrogen peroxide or inorganic peroxides or peracids
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/70Complexes comprising metals of Group VII (VIIB) as the central metal
    • B01J2531/72Manganese

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epoxy Compounds (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CR20190113A 2016-08-05 2017-08-03 Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma CR20190113A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371686P 2016-08-05 2016-08-05
US201762536862P 2017-07-25 2017-07-25
PCT/US2017/045274 WO2018027021A1 (en) 2016-08-05 2017-08-03 Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof

Publications (1)

Publication Number Publication Date
CR20190113A true CR20190113A (es) 2019-04-25

Family

ID=59593230

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190113A CR20190113A (es) 2016-08-05 2017-08-03 Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma

Country Status (29)

Country Link
US (1) US11708341B2 (es)
EP (1) EP3494108B1 (es)
JP (1) JP7229912B2 (es)
KR (1) KR102482663B1 (es)
CN (1) CN109641863B (es)
AU (1) AU2017306546B2 (es)
BR (1) BR112019002191A2 (es)
CA (1) CA3032963A1 (es)
CL (1) CL2019000294A1 (es)
CO (1) CO2019001139A2 (es)
CR (1) CR20190113A (es)
CY (1) CY1124363T1 (es)
DK (1) DK3494108T3 (es)
ES (1) ES2842575T3 (es)
HU (1) HUE051980T2 (es)
IL (1) IL264549B (es)
JO (1) JOP20190016B1 (es)
LT (1) LT3494108T (es)
MX (1) MX2019001459A (es)
PE (1) PE20190404A1 (es)
PH (1) PH12019500232A1 (es)
PL (1) PL3494108T3 (es)
PT (1) PT3494108T (es)
SG (2) SG11201900991UA (es)
SI (1) SI3494108T1 (es)
TN (1) TN2019000028A1 (es)
UA (1) UA125648C2 (es)
WO (1) WO2018027021A1 (es)
ZA (1) ZA201900717B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114195741A (zh) * 2021-12-28 2022-03-18 南京格亚医药科技有限公司 一种卡非佐米关键中间体异构体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US20050256324A1 (en) * 2004-05-10 2005-11-17 Proteolix, Inc. Synthesis of amino acid keto-epoxides
JP2006028154A (ja) 2004-06-14 2006-02-02 Sumitomo Chemical Co Ltd 光学活性化合物の製造方法
HUE027850T2 (en) 2004-12-07 2016-11-28 Onyx Therapeutics Inc Preparation for proteasome inhibition
DK2207791T4 (da) 2007-10-04 2019-10-07 Onyx Therapeutics Inc Krystallinske peptidepoxyketon-proteasehæmmere og syntese af aminosyreketoepoxider
ES2617560T3 (es) 2008-10-21 2017-06-19 Onyx Therapeutics, Inc. Combinación del inhibidor del proteasoma de epoxicetona peptídica carfilzomib con melfalán para su uso en el tratamiento del mieloma múltiple
US20130303482A1 (en) 2012-05-08 2013-11-14 Onyx Therapeutics, Inc. Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors
EP2869820A4 (en) 2012-07-09 2016-02-17 Onyx Therapeutics Inc PRODRUGS OF PEPTIDEPOXIDE KETONE PROTEASE INHIBITORS
US10022326B2 (en) 2012-07-18 2018-07-17 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
DE102013104003B3 (de) 2013-04-19 2014-03-13 Glatt Systemtechnik Gmbh Vorrichtung zum Einbringen einer definierten Menge eines zweiten Pulvers in einen Prozessbehälter
CN104230857A (zh) * 2014-08-19 2014-12-24 上海皓元生物医药科技有限公司 卡非佐米(Carfilzomib)的中间体化合物的制备方法及其中间体化合物

Also Published As

Publication number Publication date
SG11201900991UA (en) 2019-03-28
CL2019000294A1 (es) 2019-05-03
BR112019002191A2 (pt) 2019-05-21
SI3494108T1 (sl) 2021-02-26
EP3494108B1 (en) 2020-10-28
MX2019001459A (es) 2019-06-20
JOP20190016A1 (ar) 2019-02-04
SG10201912268UA (en) 2020-02-27
JP2019525945A (ja) 2019-09-12
JOP20190016B1 (ar) 2023-03-28
PE20190404A1 (es) 2019-03-13
AU2017306546A1 (en) 2019-02-21
KR102482663B1 (ko) 2022-12-29
PH12019500232A1 (en) 2019-10-21
UA125648C2 (uk) 2022-05-11
EP3494108A1 (en) 2019-06-12
CN109641863B (zh) 2023-10-20
LT3494108T (lt) 2021-01-25
KR20190039184A (ko) 2019-04-10
JP7229912B2 (ja) 2023-02-28
CA3032963A1 (en) 2018-02-08
CO2019001139A2 (es) 2019-02-19
TN2019000028A1 (en) 2020-07-15
US11708341B2 (en) 2023-07-25
DK3494108T3 (da) 2021-01-11
IL264549B (en) 2022-02-01
ZA201900717B (en) 2023-06-28
US20210284617A1 (en) 2021-09-16
HUE051980T2 (hu) 2021-04-28
PL3494108T3 (pl) 2021-04-19
CY1124363T1 (el) 2022-07-22
ES2842575T3 (es) 2021-07-14
PT3494108T (pt) 2021-01-05
CN109641863A (zh) 2019-04-16
AU2017306546B2 (en) 2021-10-21
WO2018027021A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
ECSP18093777A (es) Derivados de pirazolopirimidina como inhibidor de quinasa
MX2018011139A (es) Acido acrilico y metodos para producir el mismo.
WO2016011390A8 (en) Irak4 inhibiting agents
CR20160538A (es) Combinación
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
MX370611B (es) Metodos utiles en la sintesis de analogos de halicondrina b.
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
AR102767A1 (es) Inhibidores de ezh2
MX2018014176A (es) Capsulas que comprenden bencilpropargileteres para usar como inhibidores de la nitrificacion.
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
NI201800071A (es) Compuestos de isoindol
MX2022006768A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MY193239A (en) Novel b-lactamase inhibitors
EA201892235A1 (ru) Гранулированная композиция для перорального применения
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
MX2019007826A (es) Activador nrf2.
CR20190113A (es) Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma
EP4335500A3 (en) Methods for the synthesis of deuterated dextromethorphan
MX2019002065A (es) Derivado de triazolopirazinona util como un inhibidor de pde1 humana.
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
AR107163A1 (es) Inhibidores de quinasa
IN2014MU01193A (es)